Filtered By:
Drug: Gilenya
This page shows you your search results in order of date.
Order by Relevance | Date
Total 88 results found since Jan 2013.
The impact of fingolimod on Treg function in brain ischaemia
In conclusion, fingolimod seems to improve the suppressive function of Treg post-stroke while also increasing the resistance of CD4+ effector cells to this suppression. Fingolimod's capacity to increase both effector and regulatory functions may explain the lack of consistent improvement in functional recovery in experimental brain ischaemia.PMID:37366289 | DOI:10.1002/eji.202350370
Source: European Journal of Immunology - June 27, 2023 Category: Allergy & Immunology Authors: Kyle Malone Jennifer A Shearer Christian Waeber Anne C Moore Source Type: research
Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
This study used a rigorous study design in normal male C57BL/6JOlaHsd mice and in mice with common stroke comorbidities to further evaluate the translational potential of fingolimod. Stroke was induced via middle cerebral artery electrocoagulation in 8-9-week old mice (young mice), 18 month old mice (aged mice), and in high-fat diet-fed 22-week old ApoE-/- mice (hyperlipidaemic mice). Recovery was evaluated using motor behavioural tests 3 and 7 days after stroke. Tissue damage was evaluated at 7 days. A lower dose of fingolimod, 0.5 mg/kg, but not 1 mg/kg, increased lesion size but decreased ipsilateral brain atrophy in yo...
Source: Atherosclerosis - August 1, 2022 Category: Cardiology Authors: Andrea C Diaz Diaz Kyle Malone Jennifer A Shearer Anne C Moore Christian Waeber Source Type: research
Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications
Adv Pharmacol. 2022;94:95-139. doi: 10.1016/bs.apha.2022.02.001. Epub 2022 Mar 30.ABSTRACTSphingosine-1-phosphate (S1P) is a lipid that binds and activates five distinct receptor subtypes, S1P1, S1P2, S1P3, S1P4, S1P5, widely expressed in different cells, tissues and organs. In the cardiovascular system these receptors have been extensively studied, but no drug acting on them has been approved so far for treating cardiovascular diseases. In contrast, a number of S1P receptor agonists are approved as immunomodulators, mainly for multiple sclerosis, because of their action on lymphocyte trafficking. This chapter summarizes t...
Source: Advances in Pharmacology - June 6, 2022 Category: Drugs & Pharmacology Authors: Simona Federica Spampinato Maria Angela Sortino Salvatore Salomone Source Type: research
